Development of new microbiota-inspired compounds for the validation of NPM1 protein as a therapeutic target for acute myeloid leukemia

Despite early diagnosis and the development of new treatments, many patients with acute myeloid leukemia (AML) continue to fail therapy, resulting in relapses and more aggressive cancers with poor prognosis. Therefore, the development of new therapies targeting critical genetic mutations affecting A...

Descripción completa

Detalles Bibliográficos
Autor: Sánchez Merino, Anabel
Tipo de recurso: tesis doctoral
Fecha de publicación:2024
País:España
Institución:Universidad Complutense de Madrid (UCM)
Repositorio:Docta Complutense
Idioma:inglés
OAI Identifier:oai:docta.ucm.es:20.500.14352/118975
Acceso en línea:https://hdl.handle.net/20.500.14352/118975
Access Level:acceso abierto
Palabra clave:616.155.392-036.11(043.2)
Leucemia mieloide aguda
Química
23 Química
id ES_f3a268ae7c1fccca28ecdc0c9aede57b
oai_identifier_str oai:docta.ucm.es:20.500.14352/118975
network_acronym_str ES
network_name_str España
repository_id_str
spelling Development of new microbiota-inspired compounds for the validation of NPM1 protein as a therapeutic target for acute myeloid leukemiaDesarrollo de nuevos compuestos inspirados en la microbiota para la validación de la proteína NPM1 como diana terapéutica de la leucemia mieloide agudaSánchez Merino, Anabel616.155.392-036.11(043.2)Leucemia mieloide agudaQuímica23 QuímicaDespite early diagnosis and the development of new treatments, many patients with acute myeloid leukemia (AML) continue to fail therapy, resulting in relapses and more aggressive cancers with poor prognosis. Therefore, the development of new therapies targeting critical genetic mutations affecting AML patients is of great importance to achieve effective treatments. In this regard, mutations in the nucleophosmine 1 gene (NPM1mut) represent the most common genetic alteration found in AML patients...Universidad Complutense de MadridLópez Rodríguez, María LuzBenhamú Salama, BellindaVázquez Villa, María Del HenarUniversidad Complutense de Madrid20242024-02-2520242024-02-25doctoral thesishttp://purl.org/coar/resource_type/c_db06info:eu-repo/semantics/doctoralThesisapplication/pdfhttps://hdl.handle.net/20.500.14352/118975reponame:Docta Complutenseinstname:Universidad Complutense de Madrid (UCM)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:docta.ucm.es:20.500.14352/1189752026-06-02T12:44:21Z
dc.title.none.fl_str_mv Development of new microbiota-inspired compounds for the validation of NPM1 protein as a therapeutic target for acute myeloid leukemia
Desarrollo de nuevos compuestos inspirados en la microbiota para la validación de la proteína NPM1 como diana terapéutica de la leucemia mieloide aguda
title Development of new microbiota-inspired compounds for the validation of NPM1 protein as a therapeutic target for acute myeloid leukemia
spellingShingle Development of new microbiota-inspired compounds for the validation of NPM1 protein as a therapeutic target for acute myeloid leukemia
Sánchez Merino, Anabel
616.155.392-036.11(043.2)
Leucemia mieloide aguda
Química
23 Química
title_short Development of new microbiota-inspired compounds for the validation of NPM1 protein as a therapeutic target for acute myeloid leukemia
title_full Development of new microbiota-inspired compounds for the validation of NPM1 protein as a therapeutic target for acute myeloid leukemia
title_fullStr Development of new microbiota-inspired compounds for the validation of NPM1 protein as a therapeutic target for acute myeloid leukemia
title_full_unstemmed Development of new microbiota-inspired compounds for the validation of NPM1 protein as a therapeutic target for acute myeloid leukemia
title_sort Development of new microbiota-inspired compounds for the validation of NPM1 protein as a therapeutic target for acute myeloid leukemia
dc.creator.none.fl_str_mv Sánchez Merino, Anabel
author Sánchez Merino, Anabel
author_facet Sánchez Merino, Anabel
author_role author
dc.contributor.none.fl_str_mv López Rodríguez, María Luz
Benhamú Salama, Bellinda
Vázquez Villa, María Del Henar
Universidad Complutense de Madrid
dc.subject.none.fl_str_mv 616.155.392-036.11(043.2)
Leucemia mieloide aguda
Química
23 Química
topic 616.155.392-036.11(043.2)
Leucemia mieloide aguda
Química
23 Química
description Despite early diagnosis and the development of new treatments, many patients with acute myeloid leukemia (AML) continue to fail therapy, resulting in relapses and more aggressive cancers with poor prognosis. Therefore, the development of new therapies targeting critical genetic mutations affecting AML patients is of great importance to achieve effective treatments. In this regard, mutations in the nucleophosmine 1 gene (NPM1mut) represent the most common genetic alteration found in AML patients...
publishDate 2024
dc.date.none.fl_str_mv 2024
2024-02-25
2024
2024-02-25
dc.type.none.fl_str_mv doctoral thesis
http://purl.org/coar/resource_type/c_db06
dc.type.openaire.fl_str_mv info:eu-repo/semantics/doctoralThesis
format doctoralThesis
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.14352/118975
url https://hdl.handle.net/20.500.14352/118975
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidad Complutense de Madrid
publisher.none.fl_str_mv Universidad Complutense de Madrid
dc.source.none.fl_str_mv reponame:Docta Complutense
instname:Universidad Complutense de Madrid (UCM)
instname_str Universidad Complutense de Madrid (UCM)
reponame_str Docta Complutense
collection Docta Complutense
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869424395850612736
score 15,81155

Similares en LA Referencia